Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
According to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.
Data from the DanGer Shock trial demonstrate that implantation of a microaxial flow pump in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock increases the survival rate compared with standard care alone.
Three randomized clinical trials presented at ACC.24 demonstrate that olezarsen and plozasiran, RNA-based therapies that target APOC3, can robustly reduce plasma triglyceride levels in patients with moderate to severe hypertriglyceridaemia.
The under-representation of women in cardiovascular clinical trials persists across participant, clinician and research roles. This gap perpetuates health inequity and hampers the generation, translation and implementation of optimal evidence-based care. Urgent action is needed to address barriers, promote diversity, and ensure inclusive trial design and health-care delivery and dissemination, for more equitable cardiovascular health.
In the REDUCE-AMI trial, the use of β-blockers in patients with acute myocardial infarction (MI) who have undergone early coronary angiography and have a preserved left ventricular ejection fraction did not reduce the risk of death or new MI compared with no β-blocker use.
In patients with symptomatic aortic stenosis and a small aortic annulus, a self-expanding valve has similar rates of clinical outcomes at 1 year and lower rates of bioprosthetic dysfunction compared with a balloon-expandable valve.
After myocardial infarction, the heart secretes small extracellular vesicles with pro-neoplastic properties that can accelerate tumour growth when taken up by cancer cells.
In ST-segment elevation myocardial infarction, the role of interventional modification of thrombi in the coronary arteries before stenting is controversial. However, innovations in stroke intervention have sparked renewed interest in thrombus modification approaches. We discuss current and emerging techniques to extract or disperse thrombi, aiming to reduce downstream embolization, microvascular obstruction and myocardial injury.
A new study identifies a hormone that is secreted by the gut in response to cholesterol absorption and can inhibit cholesterol synthesis in the liver, which prevents an increase in circulating cholesterol levels.
In patients with carotid artery disease, the presence of microplastics and nanoplastics in the carotid plaque is associated with an increased risk of death or major cardiovascular events compared with patients in whom microplastics and nanoplastics were not detected.
In this Tools of the Trade article, Trivett discusses the potential of long-read sequencing in generating high-quality reference genomes of animal models of cardiovascular disease.
In this Tools of the Trade article, Charrière describes the FluoStep FRET-based biosensor used for high-resolution imaging of cAMP nanodomains that are involved in intracellular signalling in cardiomyocytes.
Novel cardiovascular therapeutics have the potential to improve health outcomes, but financial toxicity from high out-of-pocket costs can limit the reach of these medications and worsen existing health disparities. Understanding the phenomenon of financial toxicity in treating cardiovascular disease is crucial to achieving health equity.
In this Tools of the Trade article, Olivera describes a rat model of pre-elampsia that has been instrumental for investigating potential long-term cardiovascular effects in offspring.
A new approach to modify the epigenome can lead to durable silencing of Pcsk9 in mice, thereby reducing plasma LDL-cholesterol levels, according to a study published in Nature.
Shoaran and Maffia recount how our understanding of the role of inflammation in atherosclerosis has evolved and highlight the study by Göran Hansson and colleagues that provided the first hint of the involvement of the adaptive immune response in atherosclerosis.
Rebecca Gilchrist discusses the study that demonstrated the long-term modulation of ventricular repolarization by the sequence of electrical activation in the human heart and established the concept of cardiac memory.
A metabolic product of excess niacin promotes vascular inflammation in preclinical models and is associated with increased rates of major adverse cardiovascular events in humans.
